Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,835 total articles

Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy

Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy

Pacira BioSciences issued a detailed statement addressing inaccurate claims made by activist investor DOMA Perpetual regarding the company's intellectual property strategy protecting its flagship non-opioid pain therapy, EXPAREL. The company highlighted the strength and recent reinforcements of its patent estate, ongoing litigation efforts against …

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma has discovered novel direct-acting antiviral compounds that target the viral replication complex enzyme L-protein, demonstrating potent activity against hantavirus, bunyavirus, and influenza. The company aims to develop broad-spectrum antiviral therapies leveraging its structure-based drug discovery platform, with initial data show…

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

Humacyte announced research presented at the VASA 2026 symposium demonstrating that its acellular tissue engineered vessel (ATEV) maintains long-term structural integrity and exhibits self-repair capabilities after repeated cannulations for dialysis access. The ATEVs showed smooth muscle cell repopulation, capillary ingrowth, collagen remodeling, a…

Lead Real Estate Introduces JINRYU HOTEL series, a Long-Stay Hospitality Concept for Japan’s Cultural Sites

Lead Real Estate Introduces JINRYU HOTEL series, a Long-Stay Hospitality Concept for Japan’s Cultural Sites

Lead Real Estate Co., Ltd, a Japanese developer listed on Nasdaq, announced the launch of the JINRYU HOTEL series, a boutique long-stay hotel brand designed to provide comfortable accommodations close to Japan's significant cultural and religious destinations. The first property, JINRYU HOTEL ISE, opened in March 2026 near the Outer Shrine of Ise J…

Rectitude Holdings Ltd Ramps up Supply Chain and Fleet Capacity Amid Surging Singapore Construction Demand

Rectitude Holdings Ltd Ramps up Supply Chain and Fleet Capacity Amid Surging Singapore Construction Demand

Rectitude Holdings Ltd, a Singapore-based safety equipment provider listed on Nasdaq, announced a significant expansion of its supply chain, stock capacity, and logistics operations in response to a 32% surge in material imports driven by Singapore's growing construction industry. The company expanded its logistics fleet, introduced same-day and ne…

Annovis Bio Regains NYSE Listing Compliance

Annovis Bio Regains NYSE Listing Compliance

Annovis Bio, Inc., a clinical-stage biotechnology company focused on treatments for Alzheimer's and Parkinson's diseases, has regained compliance with NYSE listing standards after executing corrective actions to restore market capitalization and stockholders' equity above required thresholds. The company is now focusing on advancing its Phase 3 cli…

NANO Nuclear Acquires Secured Transportation Services LLC, Establishing a Fully Integrated Nuclear Fuel Logistics and Transportation Platform and Joining a Select Group of Revenue-Generating Microreactor Developers

NANO Nuclear Acquires Secured Transportation Services LLC, Establishing a Fully Integrated Nuclear Fuel Logistics and Transportation Platform and Joining a Select Group of Revenue-Generating Microreactor Developers

NANO Nuclear Energy Inc. (NASDAQ: NNE) announced the acquisition of Secured Transportation Services LLC (STS), a specialized nuclear logistics and transportation company. This acquisition enables NANO Nuclear to integrate a critical segment of the nuclear fuel cycle, specifically in the planning, coordination, licensing, and secure transportation o…

Sharplink to Join the Russell 2000 and 3000 Indexes

Sharplink to Join the Russell 2000 and 3000 Indexes

Sharplink, Inc., a major institutional holder of Ethereum and proponent of Ethereum adoption, revealed it will be added to the Russell 2000 and 3000 indexes effective June 29, 2026. This inclusion is expected to enhance Sharplink’s exposure to institutional investors and expand its shareholder base. The company emphasizes its role in providing publ…

ZenaTech Opens New Chapter of Growth Through Partnerships — Inviting Founder-Led Companies to Join Its Platform in Defense, Enterprise SaaS and AI Infrastructure

ZenaTech Opens New Chapter of Growth Through Partnerships — Inviting Founder-Led Companies to Join Its Platform in Defense, Enterprise SaaS and AI Infrastructure

ZenaTech, a Nasdaq-listed technology company specializing in AI-driven drone platforms, enterprise SaaS, and quantum computing solutions, announced a new growth strategy inviting profitable, founder-led companies in defense technology, enterprise SaaS, AI infrastructure, and related sectors to join its platform. The partnership program focuses on c…

Quantum Cyber Strengthens Balance Sheet with Over $15 Million in Aggregate Financing; Cap Table is Debt-Free

Quantum Cyber Strengthens Balance Sheet with Over $15 Million in Aggregate Financing; Cap Table is Debt-Free

Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, announced that warrant holders have fully exercised their warrants, generating over $15 million in gross proceeds. The company is now debt-free and plans to use the funds to expand R&D, build out its commercialization team, and pursue strategic acquisitions to advance its AI…

J-Star Holding Subsidiary Receives Central Bank of Taiwan Authorization to Initiate $60 Million Sovereign-Backed Financing Framework through Designated Banks for U.S. Solid-State Battery Expansion ($122.5 Million Project)

J-Star Holding Subsidiary Receives Central Bank of Taiwan Authorization to Initiate $60 Million Sovereign-Backed Financing Framework through Designated Banks for U.S. Solid-State Battery Expansion ($122.5 Million Project)

J-Star Holding’s subsidiary YMA Corporation has obtained authorization from the Central Bank of Taiwan to access a $60 million sovereign-backed financing framework supporting the company’s $122.5 million investment in a 100MWh solid-state battery manufacturing facility in Baytown, Texas. The project aims to bolster U.S. advanced manufacturing capab…

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus Therapeutics announced new health economics data showing their CNSide cerebrospinal fluid assay enables earlier diagnosis and therapeutic management of leptomeningeal metastases (LM), potentially reducing healthcare costs by approximately 33-47%. This was presented at the ISPOR 2026 Annual Meeting and highlights CNSide's impact in lowering inp…

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics announced that the independent Data Safety Monitoring Board (DSMB) has given its sixth consecutive positive recommendation to continue the pivotal Phase 3 Bria-ABC study evaluating Bria-IMT combined with an immune checkpoint inhibitor in metastatic breast cancer patients. The DSMB found no safety concerns. The study is conduct…

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics has submitted a Biologics License Application to the U.S. FDA for accelerated approval of z-rostudirsen (DYNE-251), a treatment targeting Duchenne Muscular Dystrophy patients amenable to exon 51 skipping. The submission is based on significant results from the DELIVER trial showing increased dystrophin production and functional im…

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics announced multiple presentations at the 2026 CMSC annual meeting highlighting clinical and real-world data supporting BRIUMVI® (ublituximab-xiiy) as an effective treatment for relapsing forms of multiple sclerosis (RMS). New Phase 4 ENABLE study results demonstrate significant improvements in patient-reported outcomes and sustained …

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Streamex Corp. (NASDAQ: STEX), a technology company specializing in tokenization of real-world assets, announced the appointment of Kori Handy as Vice President of Product and Design. With 18 years of fintech and SaaS experience, Handy will lead the transformation of Streamex’s GLDY platform and future products to improve user experience and accele…

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Pharma announced positive independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study demonstrating statistically significant genuine neural recovery with NVG-291 in chronic tetraplegia patients. 100% of treated subjects were responders versus 10% placebo, supporting NVG-291 as a potentially best-in-class restora…

Global-e to Enhance Logistics Offering with Acquisition of Passport, a US-based e-Commerce Logistics and Solutions Company

Global-e to Enhance Logistics Offering with Acquisition of Passport, a US-based e-Commerce Logistics and Solutions Company

Global-e Online Ltd., a leading global direct-to-consumer e-commerce platform, announced its definitive agreement to acquire Passport Global Inc., a US-based cross-border e-commerce logistics company. The acquisition aims to deepen Global-e's logistics and trade compliance capabilities, improve the post-purchase experience, and expand service offer…

California Resources Corporation Achieves First CO₂ Injection at Carbon TerraVault I, a Major Milestone for Carbon Management in California

California Resources Corporation Achieves First CO₂ Injection at Carbon TerraVault I, a Major Milestone for Carbon Management in California

California Resources Corporation (NYSE: CRC) announced the first CO2 injection at its Carbon TerraVault I project, marking the launch of California's first operational carbon capture and storage (CCS) initiative. Located at the Elk Hills Field in Kern County, the project stores CO2 underground in depleted reservoirs, supporting California's carbon …

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, including an initial $50 million tranche, extending its cash runway into 2028. The funding supports advancement of its lead cell therapy candidate Descartes-08 through multiple clinical programs targeting autoimmune diseases such as myasthenia gr…